PRURITUS THERAPEUTICS MARKET ANALYSIS

Regional Analysis

Global Pruritus Therapeutics Market  – Regional Insights

Among regions, North America is expected to account for the largest share in global pruritus therapeutics market over the forecast period, owing to the approval of treatments from regulatory authorities for treatment of pruritus. For instance, on March 8, 2021, the U.S. Food and Drugs Administration (FDA) accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.  The Prescription Drug User Fee Act (PDUFA) target action date for KORSUVA is August 23, 2021. KORSUVA is marketed by Vifor Pharma, a global pharmaceutical company, which develops products for precision patient care and Cara Therapeutics, Inc., a clinical stage biopharmaceutical company focused on producing new chemical entities to alleviate pruritus.

Moreover, due to rise in agreements and sales partnerships within market players, Europe may witness a lucrative growth in global pruritus therapeutics market over the forecast period. For instance, on February 17, 2021, Almirall S.A., a global biopharmaceutical company, and MC2 Therapeutics, a commercial stage pharmaceutical company, which develops topical therapies for autoimmune and chronic inflammatory conditions, confirmed that MC2 Therapeutics granted Almirall exclusive European rights to commercialize WYNZORA Cream for the treatment of plaque psoriasis, a common cause of psoriasis itching (pruritus) in adults. These factors are expected to support global pruritus therapeutics market growth over the forecast period.